Objective: To evaluate the effect of opicapone (OPC) 50 mg versus entacapone (ENT) on early morning-OFF (EMO) pattern.

Background:
OPC, a once-daily catechol-O-methyltransferase inhibitor, was shown to be effective for end-of-dose motor fluctuations in Parkinson’s disease (PD) patients in two large multinational trials (BIPARK-I and II) [1, 2].